Jim Simons
XLO icon

Jim Simons’s Xilio Therapeutics XLO Stock Holding History

Jim Simons’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$615K Buy
64,153
+14,587
+29% +$122K ﹤0.01% 2525
2026
Q1 		$417K Buy
49,566
+24,965
+101% +$204K ﹤0.01% 2672
2025
Q4 		$220K Buy
24,601
+9,980
+68% +$105K ﹤0.01% 2862
2025
Q3 		$173K Buy
14,621
+2,892
+25% +$29K ﹤0.01% 3159
2025
Q2 		$112K Sell
11,729
-964
-8% -$10.2K ﹤0.01% 3283
2025
Q1 		$129K Sell
12,693
-8,494
-40% -$107K ﹤0.01% 3154
2024
Q4 		$283K Buy
21,187
+2,166
+11% +$29.8K ﹤0.01% 3061
2024
Q3 		$210K Sell
19,021
-2,050
-10% -$25.2K ﹤0.01% 3111
2024
Q2 		$280K Buy
21,071
+3,253
+18% +$50.9K ﹤0.01% 2935
2024
Q1 		$269K Buy
17,818
+2,839
+19% +$27.4K ﹤0.01% 3129
2023
Q4 		$115K Buy
14,979
+13,500
+913% +$267K ﹤0.01% 3271
2023
Q3 		$44K Buy
1,479
+29
+2% +$1.08K ﹤0.01% 3425
2023
Q2 		$53K Buy
1,450
+107
+8% +$4.55K ﹤0.01% 3607
2023
Q1 		$60K Sell
1,343
-1,307
-49% -$57.4K ﹤0.01% 3619
2022
Q4 		$100K Buy
2,650
+614
+30% +$20.7K ﹤0.01% 3617
2022
Q3 		$83K Sell
2,036
-3,343
-62% -$130K ﹤0.01% 3651
2022
Q2 		$220K Buy
+5,379
New +$285K ﹤0.01% 3611

Other funds holding XLO

Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Gilead Sciences
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Stonepine Capital Management
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Sio Capital Management
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Merck & Co
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jim Simons's XLO Position: Q2 2026 in Review

Jim Simons increased its Xilio Therapeutics (XLO) stake by 29% in Q2 2026, buying an estimated $122K and bringing the position to 64,153 shares worth $615K. The position accounts for ﹤0.01% of the portfolio, ranked #2525.

Jim Simons first reported a position in XLO in Q2 2022 and has held it in 17 quarters since. 27 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Jim Simons held 64,153 shares of Xilio Therapeutics worth $615K as of Q2 2026.
  • Jim Simons bought 14,587 Xilio Therapeutics shares in Q2 2026, an estimated $122K.
  • Xilio Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2525 holding.
  • Jim Simons first reported a position in Xilio Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • 27 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.